AstraZeneca sees higher profit in 2024 on resilient demand

Strong sales of AstraZeneca's cancer treatments and rare disease drugs have fuelled revenue growth.

For 2023, AstraZeneca reported revenue of $45.8bn (€42.5bn) and core EPS of $7.26 (€6.73). Photograph Moya Nolan

AstraZeneca Plc forecast stronger-than-expected earnings growth this year, fueled by demand for its blockbuster cancer medicines.

Earnings per share will likely rise by a percentage in the low double-digits to low teens excluding some items, the drugmaker said in a statement Thursday.